Large study finds no significant overall cancer risk increase with JAK inhibitors in RA
Regulatory authorities issued precautionary recommendations following the ORAL Surveillance trial, which demonstrated an elevated risk of cancer with tofacitinib, compared to TNF inhibitors (TNFi).
Post Views: 1
